Sumitovant Biopharma completed its acquisition of Myovant Sciences originally announced Oct. 23, 2022. Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total transaction value of approximately $1.7 billion.